Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3995
Single User License Price INR 293513
Corporate User License Price USD 11985
Corporate User License Price INR 880538
Site License Price USD 7990
Site License Price INR 587025
Request a Quote

Report Title

EpiCast Report: Glaucoma-Epidemiology Forecast to 2023

Quote Request for License Type
License Type Price  
Single User License USD 3995
Site License USD 7990
Enterprise Wide License USD 11985
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

EpiCast Report: Glaucoma-Epidemiology Forecast to 2023


Quote Request for License Type
License Type Price  
Single User License USD 3995
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

EpiCast Report: Glaucoma-Epidemiology Forecast to 2023

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

EpiCast Report: Glaucoma-Epidemiology Forecast to 2023



Executive Summary

EpiCast Report: Glaucoma-Epidemiology Forecast to 2023

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye's optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. Glaucoma is generally categorized as open-angle glaucoma (OAG), angle-closure glaucoma (ACG), secondary glaucoma, and congenital glaucoma. Other less common types of glaucoma include normal-tension glaucoma (NTG), pseudoexfoliation glaucoma, and pigmentary glaucoma (NEI, 2014b). Although there are many types of glaucoma, the two most important types are OAG and ACG, with OAG accounting for about 80-90% of all glaucoma cases (Mayo Clinic, 2014). OAG and ACG can be primary (primary open-angle glaucoma [POAG] and primary angle-closure glaucoma [PACG], respectively) or secondary, depending on the cause.

GlobalData epidemiologists forecast that the total prevalent cases of glaucoma in the 7MM will grow by 14.60% over the next decade, from 13,748,430 total prevalent cases in 2013 to 15,761,674 total prevalent cases in 2023, with almost 60% of the total prevalent cases occurring in the US and Japan together.

The increase in the number of total prevalent cases of glaucoma in the 7MM can be attributed to changing population demographics in the respective markets. However, further epidemiological research is warranted given that there is a paucity of national and international data evaluating the prevalence and trends of glaucoma worldwide. There is also a need to clearly demarcate the glaucoma population in each clinical type, as currently available epidemiological literature fails to clearly demarcate different glaucoma populations.

Scope

The Glaucoma EpiCast Report provides an overview of the risk factors and global trends of glaucoma in the 7MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of total prevalent cases of glaucoma segmented by age (in five-year increments beginning at age 40), sex, clinical type (POAG, PACG, secondary glaucoma, and congenital glaucoma the total prevalent cases of NTG, which is a sub-type of OAG; and the diagnosed prevalent cases of POAG and PACG in these markets.

The glaucoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons To Buy

Develop business strategies by understanding the trends shaping and driving the global glaucoma market.

Quantify patient populations in the global glaucoma market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for glaucoma therapeutics in each of the markets covered.

Identify the percentage of glaucoma prevalent cases by clinical type.

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 Catalyst 7

2.2 Related Reports 8

2.3 Upcoming Reports 8

3 Epidemiology 9

3.1 Disease Background 9

3.2 Risk Factors and Comorbidities 11

3.3 Global Trends 13

3.3.1 US 13

3.3.2 5EU 14

3.3.3 Japan 15

3.4 Forecast Methodology 16

3.4.1 Sources Used 18

3.4.2 Forecast Assumptions and Methods 22

3.4.3 Sources Not Used 28

3.5 Epidemiological Forecast for Glaucoma (2013-2023) 29

3.5.1 Total Prevalent Cases of Glaucoma 29

3.5.2 Age-Specific Total Prevalent Cases of Glaucoma 30

3.5.3 Sex-Specific Total Prevalent Cases of Glaucoma 32

3.5.4 Age-Standardized Total Prevalence of Glaucoma 34

3.5.5 Total Prevalent Cases of Glaucoma, by Clinical Type 35

3.5.6 Total Prevalent Cases of NTG 37

3.5.7 Diagnosed Prevalent Cases of POAG and PACG 39

3.6 Discussion 42

3.6.1 Epidemiological Forecast Insight 42

3.6.2 Limitations of the Analysis 43

3.6.3 Strengths of the Analysis 44

4 Appendix 45

4.1 Bibliography 45

4.2 About the Authors 48

4.2.1 Epidemiologists 48

4.2.2 Reviewers 48

4.2.3 Global Director of Therapy Analysis and Epidemiology 49

4.2.4 Global Head of Healthcare 50

4.3 About GlobalData 51

4.4 About EpiCast 51

4.5 Disclaimer 51

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

1.2 List of Figures

Figure 1: 7MM, Total Prevalent Cases of Glaucoma, Ages ?40 Years, Both Sexes, N, 2013-2023 30

Figure 2: 7MM, Total Prevalent Cases of Glaucoma, by Age, Both Sexes, N, 2013-2023 32

Figure 3: 7MM, Total Prevalent Cases of Glaucoma, by Sex, Ages ?40 Years, N, 2013 34

Figure 4: 7MM, Age-Standardized Total Prevalence of Glaucoma, by Sex, Ages ?40 Years, %, 2013 35

Figure 5: 7MM, Total Prevalent Cases of Glaucoma, by Clinical Type, Ages ?40 Years, N, 2013 37

Figure 6: 7MM, Total Prevalent Cases of NTG, Ages ?40 Years, Both Sexes, N, 2013-2023 38

Figure 7: 7MM, Diagnosed Prevalent Cases of POAG, Ages ?40 Years, Both Sexes, N, 2013-2023 40

Figure 8: 7MM, Diagnosed Prevalent Cases of PACG, Ages ?40 Years, Both Sexes, N, 2013-2023 41

1.1 List of Tables

Table 1: Types of Glaucoma 10

Table 2: Risk Factors and Comorbidities for Glaucoma 12

Table 3: 7MM, Sources of Glaucoma Total Prevalence Data Used in the Epidemiology Forecast 17

Table 4: 7MM, Sources of Epidemiological Data Used to Forecast the Total Prevalent Cases of Glaucoma Segmented by Clinical Types 18

Table 5: 7MM, Sources Not Used in the Epidemiological Analysis of Glaucoma 28

Table 6: 7MM, Total Prevalent Cases of Glaucoma, Ages ?40 Years, Both Sexes, N, 2013-2023 29

Table 7: 7MM, Total Prevalent Cases of Glaucoma, by Age, Both Sexes, N (Row %), 2013 31

Table 8: 7MM, Total Prevalent Cases of Glaucoma, by Sex, Ages ?40 Years, N (Row %), 2013 33

Table 9: 7MM, Total Prevalent Cases of Glaucoma, by Clinical Type, Ages ?40 Years, N (Row %), 2013 36

Table 10: 7MM, Total Prevalent Cases of NTG, Ages ?40 Years, Both Sexes, N, 2013-2023 38

Table 11: 7MM, Diagnosed Prevalent Cases of POAG, Ages ?40 Years, Both Sexes, N, 2013-2023 39

Table 12: 7MM, Diagnosed Prevalent Cases of PACG, Ages ?40 Years, Both Sexes, N, 2013-2023 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand